[Temporary Announcement] Lianke Biotech: Special report on the storage and actual use of the company’s raised funds in the first half of 2026
Announcement number: 2026-023 Securities code: 831936 Securities abbreviation: Lianke Biotech Sponsoring broker: Guorong Securities
Hangzhou Lianke Biotechnology Co., Ltd.
Special report on the deposit and actual use of funds raised by the company in the first half of 2026
The Company and all members of the Board of Directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.
According to the "Measures for the Supervision and Administration of Unlisted Public Companies", "National Small and Medium Enterprises Equities Exchange and Quotations System Directed Issuance Rules", "National Small and Medium Enterprises Equities Exchange and Quotations System Directed Issuance Business Guidelines", "Answers to Frequently Asked Questions on Stock Issuance of Quoted Companies (3) - Raised Fund Management, Special Terms in Subscription Agreements, Financing of Special Types of Quoted Companies" and other relevant regulations, Hangzhou Lianke Biotechnology Co., Ltd. (hereinafter) (referred to as the "Company") The board of directors conducted a special inspection on the storage and use of raised funds as of June 30, 2026, and prepared a "Special Report on the Storage and Actual Use of the Company's Raised Funds".
1. Basic situation of raised funds
On October 25, 2021, the company held the fifth meeting of the third board of directors and the third meeting of the third board of supervisors, and reviewed and approved the "Hangzhou Lianke Biotechnology Co., Ltd. Stock Directed Issuance Prospectus" and other proposals. On November 10, 2021, the relevant proposals were reviewed and approved by the company at the 2021 sixth extraordinary general meeting of shareholders. It is determined that the company will issue 2,000,000 ordinary shares this time with an issuance price of 5.00 yuan per share and raise funds of 10,000,000 yuan.
On December 3, 2021, the National Equities Exchange and Quotations issued a "Letter on No Objection to the Directed Issuance of Stocks of Hangzhou Lianke Biotechnology Co., Ltd." (Equity Transfer System Letter (2021) No. 3987) to the company.
On December 10, 2021, the company disclosed the "Announcement on Directed Stock Issuance and Subscription" (Announcement Number: 2021-065) on the National Small and Medium-sized Enterprises Equities Exchange and Quotations Company Information Disclosure Platform.
On December 24, 2021, Shanghui Accounting Firm (Special General Partnership) issued the Shanghuishi Baozi (2021) No. 12283 capital verification report and confirmed that all the funds raised in this private placement have been received, and RMB 10,000,000 has been received. The company has deposited all raised funds in the Hangzhou Baochu Branch of Agricultural Bank of China Co., Ltd. (account number:
19030101043339993) special account.
2. Storage and management of raised funds
The company's "Raised Funds Management System" stipulates the management, use, supervision and accountability of raised funds. The company signed the "Tripartite Supervision Agreement on Raised Funds" with the Hangzhou Baochu Branch of Agricultural Bank of China Co., Ltd.
Announcement No.: 2026-023 The company raised 10,000,000 yuan from the company's directional issuance, which was deposited in a special account for the raised funds. The account information is as follows: Account name: Hangzhou Lianke Biotechnology Co., Ltd.
Bank account number: 19030101043339993
Bank of deposit: Agricultural Bank of China Co., Ltd. Hangzhou Baochu Branch
The Company has strictly followed the purpose of the disclosed stock issuance plan and standardized the management of raised funds. The raised funds have not been occupied or transferred by controlling shareholders, actual controllers or other related parties.
3. Actual use of raised funds
According to the "Stock Issuance Plan (Revised)" announced by the company, the funds raised by the company will be used to supplement working capital and R&D investment.
As of June 30, 2026, the company's use of funds raised this time is as follows:
Unit: Yuan
The actual amount of funds expected to be raised in the issuance plan
Amount of funds
- Total raised funds 10,000,000.00 10,000,000.00 plus: interest income less net handling fees 20,882.09 Total usable raised funds in this period 10,020,882.09
Estimated use in distribution plan
2. Use of raised funds Actual amount used
Amount
Among them:
Supplementary working capital 2,500,000.00 2,423,082.24 Research and development investment 7,500,000.00 7,580,717.77 Total 10,000,000.00 10,003,800.01
3. Unused raised funds on June 30, 2026
Amount of 17,082.08
4. Changes in the use of raised funds
As of June 30, 2026, the company has not changed the use of raised funds.
5. Problems in the use and disclosure of raised funds
Information related to the company's raised funds and subscriptions are disclosed in a timely, true, accurate and complete manner on the National Small and Medium Enterprises Share Transfer System Information Disclosure Platform. In the use of the company's raised funds, there is no failure to perform the review and approval process for changing the use of raised funds, no illegal use of raised funds to hold trading financial assets and available-for-sale financial assets, lending to others, entrusted financial management and other financial investments, and no direct or indirect investment of raised funds in buying and selling securities.
Announcement No.: 2026-023 For companies whose main business is business, there is no situation where the raised funds are occupied or transferred by the controlling shareholder, actual controller or other related parties.
6. Concluding opinions on the deposit and actual use of the company’s raised funds
After verification, the board of directors believes that: as of June 30, 2026, the company's 2021 stock issuance of funds has not used the funds in advance, and there has been no change or disguised change in the investment direction of the raised funds or damage to the interests of shareholders. The deposit and actual use of the raised funds are in compliance with the relevant provisions of laws and regulations such as the "Measures for the Supervision and Administration of Unlisted Public Companies", the "Guidelines for the National Equities Exchange and Quotations", the "National Equities Exchange and Quotations" and other laws and regulations.
Hangzhou Lianke Biotechnology Co., Ltd.
board of directors
August 25, 2026